Fennec Pharmaceuticals (Fennec Pharmaceuticals) Days Sales Outstanding : 34.32 (As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Fennec Pharmaceuticals Days Sales Outstanding?

Fennec Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2024 was $9.54 Mil. Fennec Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $25.38 Mil. Hence, Fennec Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 34.32.

The historical rank and industry rank for Fennec Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

FENC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.03 Med: 228.29 Max: 367.45
Current: 45.03

During the past 13 years, Fennec Pharmaceuticals's highest Days Sales Outstanding was 367.45. The lowest was 45.03. And the median was 228.29.

FENC's Days Sales Outstanding is ranked better than
73.87% of 888 companies
in the Biotechnology industry
Industry Median: 72.34 vs FENC: 45.03

Fennec Pharmaceuticals's Days Sales Outstanding declined from Mar. 2023 (87.82) to Mar. 2024 (34.32).

Fennec Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Fennec Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Days Sales Outstanding Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

367.38

88.96

Fennec Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															87.82	56.64	48.81	62.52	34.32

Competitive Comparison of Fennec Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Fennec Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Days Sales Outstanding falls into.

Fennec Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Fennec Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1.545	+	8.814)	/	2 )	/	21.252	*	365
=	5.1795					/	21.252	*	365
=	88.96

Fennec Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (8.814	+	10.274)	/	2 )	/	25.377	*	365 / 4
=	9.544					/	25.377	*	365 / 4
=	34.32

Fennec Pharmaceuticals (NAS:FENC) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Fennec Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (Fennec Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (NAS:FENC) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

RV41:Germany FRX:Canada

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Executives

Robert Andrade	officer: Chief Financial Officer	C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Rosty Raykov	director, officer: Chief Executive Officer	C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Chris A Rallis	director	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Adrian Haigh	director	83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27
Marco Maria Brughera	director	VIALE STEFINI 14, MILANO L6 00000
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Shubh Goel	officer: Chief Commercial Officer	1100 MAXWELL, #522, HOBOKEN NJ 07030
Southpoint Capital Advisors Lp	10 percent owner	1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Jodi A Cook	director	PO BOX 816, NEWTOWN PA 08540
Manchester Management Pr, Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Francesca Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Paolo Cavazza	10 percent owner	VIA TESSERETE, 10, LUGANO V8 V8
Silvia Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040